Chemical.AI

Chemical.AI (智化科技) is an AI-powered chemical synthesis company founded in 2018 by Ning Xia, who holds a doctorate in organic chemistry from the French Academy of Sciences and has spent over a decade working at the intersection of computation and chemical synthesis . The company applies machine learning and chemical big data to solve preclinical synthesis problems in drug discovery, with a particular focus on retrosynthesis—using custom algorithms to predict viable reaction pathways and integrate valuable data for reaction prediction .

In its early positioning, Chemical.AI was described by investor FreeS Fund as taking a distinctive path among AI chemistry approaches: rather than pure data-driven learning, it employed "machine learning guided by chemist experience," making the process interpretable and adjustable while avoiding human bias . By 2021, the company had established itself as a recognized player in AI-assisted chemical synthesis, having raised nearly $15 million in a Series A+ round led by Source Code Capital with participation from Sequoia China, FreeS Fund, and Huafang Capital . Its products had reportedly been adopted by top global pharmaceutical companies and major CROs, and it was building out a closed-loop model combining data, CRO services, and robotics .

The company's evolution also reflects broader shifts in how AI is applied to scientific research. While early materials emphasized Chemical.AI's role in software-based synthesis route design , later coverage placed it within a wider landscape where AI tools were being integrated with automation and experimental validation to move toward more fully intelligent R&D systems .